IP Library › Granted Patent US 7,803,748
Granted Patent B2
US 7,803,748 · App. 11/881,217 · Granted Sep 28, 2010

Nanoparticles for protein drug delivery

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,803,748
App. No.
11/881,217
Granted
Sep 28, 2010
Kind
B2
Abstract

The invention discloses the nanoparticles composed of chitosan, poly-γ-glutamic acid, and at least one bioactive agent characterized with a positive surface charge and their enhanced permeability for paracellular drug delivery.

Claims (25)

1. A pharmaceutical composition of nanoparticles wherein the nanoparticles enhance paracellular transport of at least one bioactive agent, each nanoparticle consisting of:

a) at least one bioactive agent,

b) low molecular weight chitosan, and

c) a negatively charged organic compound,

wherein the low molecular weight chitosan dominates the surface of the said nanoparticle, and

wherein the negatively charged organic compound is complexed with a substantial portion of said low molecular weight chitosan.

2. The pharmaceutical composition of claim 1 , wherein the surface of the nanoparticles has a positive surface charge.

3. The pharmaceutical composition of claim 1 , wherein said negatively charged organic compound is a polyglutamic acid or salt of said polyglutamic acid.

4. The pharmaceutical composition of claim 1 , wherein negatively charged organic compound is γ-PGA, α-PGA, or a salt thereof.

5. The pharmaceutical composition of claim 1 , wherein said negatively charged organic compound is alginate.

6. The pharmaceutical composition of claim 5 , wherein the alginate has a molecular weight of about 50 kDa or less.

7. The pharmaceutical composition of claim 1 , wherein the at least one bioactive agent is a growth factor.

8. The pharmaceutical composition of claim 1 , wherein the at least one bioactive agent is oxytocin.

9. The pharmaceutical composition of claim 1 , wherein the at least one bioactive agent is a hormone.

10. The pharmaceutical composition of claim 1 , wherein the at least one bioactive agent is erythropoietin.

11. The pharmaceutical composition of claim 1 , wherein said nanoparticles are further encapsulated in a capsule.

12. The pharmaceutical composition of claim 1 , wherein the low molecular weight chitosan has a molecular weight of about 80 kDa or less.

13. The pharmaceutical composition of claim 1 , wherein the low molecular weight chitosan has a molecular weight of about 40 kDa or less.

14. The pharmaceutical composition of claim 1 , wherein the at least one bioactive agent is a monoclonal antibody.

15. The pharmaceutical composition of claim 1 , wherein the at least one bioactive agent is a growth hormone.

16. The pharmaceutical composition of claim, 1 , wherein the at least one bioactive agent is an antiviral agent.

17. The pharmaceutical composition of claim 1 , wherein the at least one bioactive agent is an antineoplastic agent.

18. The pharmaceutical composition of claim 1 , wherein the at least one bioactive agent is an anti-inflammatory drug.

19. The pharmaceutical composition of claim 1 , wherein said nanoparticles are further configured in a tablet form with one or more excipients.

20. The pharmaceutical composition of claim 1 , wherein the at least one bioactive agent is an Alzheimer therapeutic.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 7, 2016
From: GP MEDICAL, INC
To: NANOMEGA MEDICAL CORPORATION
Reel/Frame 038382/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 25, 2008
From: SUNG, HSING-WEN; LIANG, HSIANG-FA; LIN, YU-HSIN; TU, HOSHENG
To: GP MEDICAL, INC.
Reel/Frame 020414/0853 →